Advertisement

Topics

Sesen Bio, Inc. Company Profile

15:22 EDT 18th September 2018 | BioPortfolio

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company’s Targeted Protein Therapeutics platform. The company’s lead program, Vicinium™, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer. Vicinium incorporates a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively and effectively kill cancer cells while sparing healthy cells. For more information, please visit the company’s website at www.sesenbio.com.


News Articles [33 Associated News Articles listed on BioPortfolio]

In The Spotlight: Sesen Bio

Shares of Sesen Bio Inc. (SESN) are up more than 37% over the past 3 days while the iShares Nasdaq Biotechnology Index (ETF)(IBB) has gained a mere 1.2% for the same period.

FDA fast-tracks Sesen Bio's bladder cancer drug

The FDA granted fast-track status to Sesen Bio's Vicinium, which is in late-stage trials and is being developed as a treatmen -More- 

Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies

Eleven Biotherapeutics is rebranding itself as Sesen Bio and investors are pleased. This morning shares of Eleven are up more than 4 percent in premarket trading.

Sesen Bio Shares Plunge Despite Reporting Positive Interim Phase III Results

Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasi...

Sesen Bio nets $36.8mm through public offering

Sesen Bio Inc. (cancer drug development; formerly Eleven Biotherapeutics) netted $36.8mm through a public offering of 22.2mm common shares at $1.80. The funds will support development and commercial-s...

Sesen Bio nets $42.3mm through public offering

Sesen Bio Inc. (cancer drug development; formerly Eleven Biotherapeutics) netted $42.3mm through a public offering of 25.56mm common shares (including the overallotment) at $1.80. The funds will suppo...

Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference

Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that Stephe...

Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, tod...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Sesen Bio, Inc.

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company’s Targeted Prote...

More Information about "Sesen Bio, Inc." on BioPortfolio

We have published hundreds of Sesen Bio, Inc. news stories on BioPortfolio along with dozens of Sesen Bio, Inc. Clinical Trials and PubMed Articles about Sesen Bio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sesen Bio, Inc. Companies in our database. You can also find out about relevant Sesen Bio, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record